More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$9.85B
EPS
-12.87
P/E ratio
--
Price to sales
8.49
Dividend yield
--
Beta
-0.993388
Previous close
$427.39
Today's open
$424.08
Day's range
$418.11 - $429.94
52 week range
$353.54 - $615
show more
CEO
Bill Sibold
Employees
915
Headquarters
West Conshohocken, PA
Exchange
Nasdaq Global Select
Shares outstanding
23229561
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • 12 hours ago

Kaplan Fox Notifies Madrigal Pharmaceuticals, Inc. (MDGL) Investors of a Securities Investigation into the Company
New York, New York--(Newsfile Corp. - November 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in the Madrigal investigation, you may CLICK HERE to contact us.
Newsfile Corp • 15 hours ago

Kaplan Fox Reminds Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding an Investigation of Potential Securities Law Violations
NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in the Madrigal investigation, you may CLICK HERE to contact us.
GlobeNewsWire • Nov 16, 2026

Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (MDGL) on Behalf of Investors for Potential Securities Law Violations
New York, New York--(Newsfile Corp. - November 16, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in the Madrigal investigation, you may CLICK HERE to contact us.
Newsfile Corp • Nov 16, 2026

MDGL Investigation Notification: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
RADNOR, Pa., Nov. 14, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Madrigal Pharmaceuticals, Inc. (“Madrigal”) (NASDAQ: MDGL) on behalf of investors who purchased or acquired Madrigal securities and experienced significant financial losses.
GlobeNewsWire • Nov 14, 2026

Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (MDGL) and Encourages Investors Who Suffered Losses to Contact the Firm
New York, New York--(Newsfile Corp. - November 13, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in the Madrigal investigation, you may CLICK HERE to contact us.
Newsfile Corp • Nov 13, 2026

Kaplan Fox is Investigating Claims on Behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors for Potential Securities Law Violations
NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in the Madrigal investigation, you may CLICK HERE to contact us.
GlobeNewsWire • Nov 13, 2026

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
CONSHOHOCKEN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:
GlobeNewsWire • Nov 13, 2026

Kaplan Fox & Kilsheimer LLP Announces an Investigation into Madrigal Pharmaceuticals, Inc. (MDGL) for Possible Securities Law Violations
New York, New York--(Newsfile Corp. - November 12, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in the Madrigal investigation, you may CLICK HERE to contact us.
Newsfile Corp • Nov 12, 2026

Kaplan Fox Encourages Investors of Madrigal Pharmaceuticals, Inc. (MDGL) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation
New York, New York--(Newsfile Corp. - November 11, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in the Madrigal investigation, you may CLICK HERE to contact us.
Newsfile Corp • Nov 11, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Madrigal Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.